|
HANGZHOU, China, June 8, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190; "Zylox-Tonbridge" or the "Company"), a Hong Kong-listed medical technology company focused on neurovascular and peripheral vascular interventional products and solutions, announced that it has been recognized as a Most Honored Company in Extel's 16th Asia (ex-Japan/ANZ) Executive Team Survey.
The recognition reflects the international investment community's confidence in the Company's management capabilities, governance standards, disclosure transparency and investor communication quality, as well as its long-term commitment to sound governance and steady development.
In this survey, Zylox-Tonbridge was also recognized across multiple categories in the Healthcare Equipment & Services sector, including Best CEO, Best CFO, Best IR Program, Best IR Team and Best IR Professional.
Extel, formerly Institutional Investor Research, is an independent research and rankings provider widely followed by the global capital markets. Its Asia Executive Team rankings are based on votes from global investors, portfolio managers and analysts, with a focus on listed companies' management teams, investor relations, corporate governance, ESG performance and boards. According to Extel, the 2026 Asia Executive Team Survey attracted participation from 5,581 investors, portfolio managers and analysts from 1,249 voter firms, covering 2,520 companies and 2,728 individuals across 23 sectors.
"We are honored to receive recognition from Extel, as well as international investors and analysts," said Dr. Jonathon Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge. "This honor reflects the capital market's recognition of our corporate governance standards and management team. It also encourages us to remain focused on long-term value creation and to continuously enhance our investor relations management. Looking ahead, we will continue to deepen our innovation-driven and international development strategies, advance product development, commercialization capabilities and global market expansion, and bring more high-quality and accessible innovative solutions to patients worldwide, while continuing to enhance the Company's long-term value."
About Zylox-Tonbridge
Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) is a medical technology company dedicated to the innovative research and development, manufacturing and commercialization of medical devices in the field of vascular intervention. Founded in 2012 and headquartered in Hangzhou, China, the Company adheres to the brand philosophy of "Innovation for Quality Life" and is committed to providing high-quality, accessible medical devices and services.
For more information, please visit https://www.zyloxtb.com/.
HANGZHOU, China, June 8, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190; "Zylox-Tonbridge" or the "Company"), a Hong Kong-listed medical technology company focused on neurovascular and peripheral vascular interventional products and solutions, announced that it has been recognized as a Most Honored Company in Extel's 16th Asia (ex-Japan/ANZ) Executive Team Survey.
The recognition reflects the international investment community's confidence in the Company's management capabilities, governance standards, disclosure transparency and investor communication quality, as well as its long-term commitment to sound governance and steady development.
In this survey, Zylox-Tonbridge was also recognized across multiple categories in the Healthcare Equipment & Services sector, including Best CEO, Best CFO, Best IR Program, Best IR Team and Best IR Professional.
Extel, formerly Institutional Investor Research, is an independent research and rankings provider widely followed by the global capital markets. Its Asia Executive Team rankings are based on votes from global investors, portfolio managers and analysts, with a focus on listed companies' management teams, investor relations, corporate governance, ESG performance and boards. According to Extel, the 2026 Asia Executive Team Survey attracted participation from 5,581 investors, portfolio managers and analysts from 1,249 voter firms, covering 2,520 companies and 2,728 individuals across 23 sectors.
"We are honored to receive recognition from Extel, as well as international investors and analysts," said Dr. Jonathon Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge. "This honor reflects the capital market's recognition of our corporate governance standards and management team. It also encourages us to remain focused on long-term value creation and to continuously enhance our investor relations management. Looking ahead, we will continue to deepen our innovation-driven and international development strategies, advance product development, commercialization capabilities and global market expansion, and bring more high-quality and accessible innovative solutions to patients worldwide, while continuing to enhance the Company's long-term value."
About Zylox-Tonbridge
Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) is a medical technology company dedicated to the innovative research and development, manufacturing and commercialization of medical devices in the field of vascular intervention. Founded in 2012 and headquartered in Hangzhou, China, the Company adheres to the brand philosophy of "Innovation for Quality Life" and is committed to providing high-quality, accessible medical devices and services.
For more information, please visit https://www.zyloxtb.com/.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Zylox-Tonbridge Recognized as Most Honored Company in Extel 2026 Asia Executive Team Survey
GWACHEON, South Korea, June 9, 2026 /PRNewswire/ -- Park Systems Corp. (KOSDAQ: 140860), a global leader in atomic force microscopy (AFM) and nanometrology, today announced the successful completion of a KRW 100 billion (approximately USD 72 million) strategic financing through the issuance of perpetual bonds with warrants, with Kiwoom Securities and Dominus Investment Management each subscribing KRW 50 billion. The proceeds will support the company's production capacity expansion and broader strategic initiatives as demand for precision nanometrology continues to grow across the semiconductor and advanced materials industries.
The bonds were issued at par with 0% interest for the first three years, followed by a step-up interest structure. Warrants are exercisable from June 8, 2027 to May 8, 2056 at KRW 267,747 per share, and Park Systems retains a call option to repurchase up to 20% of the bonds at par between June 2027 and June 2029.
"This financing reflects the company's commitment to scaling its manufacturing infrastructure in alignment with increasing market demand," said Karen Cho, Senior Executive Vice President at Park Systems. "As semiconductor process nodes shrink and advanced packaging architectures grow more complex, the need for sub-nanometer surface metrology has become critical across front-end and back-end semiconductor manufacturing. We believe this investment will strengthen our ability to meet growing customer demand and better serve customers worldwide."
Park Systems serves leading global chipmakers and research institutions across more than 30 countries. Building on this momentum, Park Systems reported consolidated revenue of KRW 205.6 billion in 2025. With a diversified customer base that includes major semiconductor manufacturers and a growing installed base in academic and industrial research, the company is well-positioned to capitalize on the continued expansion of nanotechnology applications worldwide.
About Park Systems
Park Systems is a global leader in nanometrology, providing advanced measurement solutions for both research and industrial applications. Founded by Dr. Sang-il Park, a contributor to the invention of atomic force microscopy (AFM) at Stanford University, the company has grown through continuous innovation and strategic acquisitions to become a leading force in the global nanometrology industry. Park Systems' technology portfolio includes AFM, white light interferometry (WLI), digital holographic microscopy (DHM), imaging spectroscopic ellipsometry (ISE), active vibration isolation systems, and solid metal probes. With regional offices across the Americas, Europe, and Asia, Park Systems supports customers in semiconductor manufacturing, materials science, and nanotechnology research.
For more information, visit www.parksystems.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Park Systems Secures KRW 100 Billion in Strategic Financing to Expand Production Capacity and Accelerate Global Growth
